Clinicopathologic features of TDO2 overexpression in renal cell carcinoma

BMC Cancer

Quoc Thang Pham¹  Wataru Yasui¹  Naoya Sakamoto¹  Takashi Babasaki¹  Kazuhiro Sentani¹  Naohide Oue¹  Go Kobayashi¹  Daiki Taniyama¹  Shintaro Akabane¹  Yohei Sekino² 

[1] Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences;Department of Urology, Hiroshima University Graduate School of Biomedical and Health Sciences;

关键词: Cancer stem cell;    PD-L1;    PTEN;    Renal cell carcinoma;    TDO2;   

DOI  :  10.1186/s12885-021-08477-1

来源: DOAJ

【 摘 要 】

Abstract Background Tryptophan 2,3-dioxygenase (TDO2) is the primary enzyme catabolizing tryptophan. Several lines of evidence revealed that overexpression of TDO2 is involved in anoikis resistance, spheroid formation, proliferation, and invasion and correlates with poor prognosis in some cancers. The aim of this research was to uncover the expression and biofunction of TDO2 in renal cell carcinoma (RCC). Methods To show the expression of TDO2 in RCC, we performed qRT-PCR and immunohistochemistry in integration with TCGA data analysis. The interaction of TDO2 with PD-L1, CD44, PTEN, and TDO2 expression was evaluated. We explored proliferation, colony formation, and invasion in RCC cells line affected by knockdown of TDO2. Results RNA-Seq and immunohistochemical analysis showed that TDO2 expression was upregulated in RCC tissues and was associated with advanced disease and poor survival of RCC patients. Furthermore, TDO2 was co-expressed with PD-L1 and CD44. In silico analysis and in vitro knockout of PTEN in RCC cell lines revealed the ability of PTEN to regulate the expression of TDO2. Knockdown of TDO2 suppressed the proliferation and invasion of RCC cells. Conclusion Our results suggest that TDO2 might have an important role in disease progression and could be a promising marker for targeted therapy in RCC. (199 words)

【 授权许可】

Unknown